Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Evommune (EVMN) Research & Development (2024 - 2025)

Evommune (EVMN) has disclosed Research & Development for 2 consecutive years, with $20.4 million as the latest value for Q4 2025.

  • Quarterly Research & Development rose 14.42% to $20.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $71.2 million through Dec 2025, changed N/A year-over-year, with the annual reading at $74.0 million for FY2025, 15.25% up from the prior year.
  • Research & Development for Q4 2025 was $20.4 million at Evommune, up from $19.6 million in the prior quarter.
  • The five-year high for Research & Development was $20.4 million in Q4 2025, with the low at $13.3 million in Q3 2024.